MEDIXA PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MEDIXA PHARMA
Largest movements
- Cash +€32,792
up €32,792 (+62.6%), from €52,395 to €85,187
mainly Net result for the year (+€54,457) and Depreciation (+€34,153)
- Tangible fixed assets -€26,407
down €26,407 (-5.0%), from €531,685 to €505,278
of which Land and buildings: -€28,452
- Reserves +€50,000
up €50,000 (+13.3%), from €375,860 to €425,860
- Debts after one year -€35,387
down €35,387 (-4.2%), from €835,716 to €800,329
of which Financial debts: -€35,387
- Other debts -€25,862
down €25,862 (-23.5%), from €110,213 to €84,351
- Gross operating margin -€2,937
down €2,937 (-2.1%), from €140,250 to €137,313
- Depreciation +€1,981
up €1,981 (+6.2%), from €32,172 to €34,153
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,455,810 | €1,456,590 | +€780 | +0.1% |
| Fixed assets | 21/28 | €1,377,804 | €1,351,397 | -€26,407 | -1.9% |
| Tangible fixed assets | 22/27 | €531,685 | €505,278 | -€26,407 | -5.0% |
| Land and buildings | 22 | €525,908 | €497,456 | -€28,452 | -5.4% |
| Plant, machinery and equipment | 23 | €2,007 | €3,076 | +€1,069 | +53.3% |
| Furniture and vehicles | 24 | €3,770 | €4,746 | +€976 | +25.9% |
| Financial fixed assets | 28 | €846,119 | €846,119 | = | 0.0% |
| Current assets | 29/58 | €78,006 | €105,193 | +€27,187 | +34.9% |
| Amounts receivable within one year | 40/41 | €25,373 | €19,759 | -€5,614 | -22.1% |
| Trade receivables | 40 | €20,872 | €19,759 | -€1,113 | -5.3% |
| Other amounts receivable | 41 | €4,501 | - | -€4,501 | |
| Cash at bank and in hand | 54/58 | €52,395 | €85,187 | +€32,792 | +62.6% |
| Deferred charges and accrued income | 490/1 | €238 | €247 | +€9 | +3.8% |
| Total equity and liabilities | 10/49 | €1,455,810 | €1,456,590 | +€780 | +0.1% |
| Equity | 10/15 | €438,141 | €492,598 | +€54,457 | +12.4% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €375,860 | €425,860 | +€50,000 | +13.3% |
| Distributable reserves | 133 | €375,860 | €425,860 | +€50,000 | +13.3% |
| Profit (loss) carried forward | 14 | €43,681 | €48,138 | +€4,457 | +10.2% |
| Amounts payable | 17/49 | €1,017,669 | €963,992 | -€53,677 | -5.3% |
| Amounts payable after more than one year | 17 | €835,716 | €800,329 | -€35,387 | -4.2% |
| Financial debts | 170/4 | €143,421 | €108,034 | -€35,387 | -24.7% |
| Other amounts payable | 178/9 | €692,295 | €692,295 | = | 0.0% |
| Amounts payable within one year | 42/48 | €165,985 | €146,593 | -€19,392 | -11.7% |
| Current portion of amounts payable after more than one year | 42 | €34,451 | €35,387 | +€936 | +2.7% |
| Trade debts | 44 | €1,176 | €2,603 | +€1,427 | +121% |
| Suppliers | 440/4 | €1,176 | €2,603 | +€1,427 | +121% |
| Taxes, remuneration and social security | 45 | €20,145 | €24,252 | +€4,107 | +20.4% |
| Taxes | 450/3 | €20,145 | €21,742 | +€1,597 | +7.9% |
| Remuneration and social security | 454/9 | - | €2,510 | +€2,510 | |
| Other amounts payable | 47/48 | €110,213 | €84,351 | -€25,862 | -23.5% |
| Accrued charges and deferred income | 492/3 | €15,968 | €17,070 | +€1,102 | +6.9% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €32,172 | €34,153 | +€1,981 | +6.2% |
| Other operating charges | 640/8 | €2,236 | €2,308 | +€72 | +3.2% |
| Gross operating margin | 9900 | €140,250 | €137,313 | -€2,937 | -2.1% |
| Operating profit (loss) | 9901 | €105,842 | €100,852 | -€4,990 | -4.7% |
| Financial income | 75/76B | €152 | €151 | -€1 | -0.7% |
| Recurring financial income | 75 | €152 | €151 | -€1 | -0.7% |
| Financial charges | 65/66B | €21,250 | €20,183 | -€1,067 | -5.0% |
| Recurring financial charges | 65 | €21,250 | €20,183 | -€1,067 | -5.0% |
| Profit (loss) for the period before taxes | 9903 | €84,744 | €80,820 | -€3,924 | -4.6% |
| Income taxes | 67/77 | €27,367 | €26,363 | -€1,004 | -3.7% |
| Profit (loss) for the period | 9904 | €57,377 | €54,457 | -€2,920 | -5.1% |
| Profit (loss) for the period to be appropriated | 9905 | €57,377 | €54,457 | -€2,920 | -5.1% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 13 October 2026 via checked.be.